• Something wrong with this record ?

Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes

K. Hemminki, LA. Kiemeney, AK. Morgans, A. Ranniko, R. Pichler, O. Hemminki, Z. Culig, P. Mulders, CH. Bangma

. 2024 ; 69 (-) : 13-20. [pub] 20240913

Status not-indexed Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24017724

UNLABELLED: Early recognition of hereditary urological cancers may influence diagnostic and therapeutic decision-making, and potentially alter the fate of patients and family members. Here, we introduce readers to the current knowledge on germline genetic testing and clinical practice in prostate, bladder, renal, and testicular carcinoma. Considering all urological cancer patients, routine inquiries about familial cancer history should become a standard practice in clinical settings. If suspicion arises, patients can opt for two avenues: referral to genetic counseling or undergoing genetic tests after consultation with the treating urologist. PATIENT SUMMARY: Tumors of the urogenital tract (prostate, kidney, bladder, and testes) can sometimes be related to genetic mutations that are present in all the cells of the body. Such mutations can be inherited and run in families. Therefore, it is relevant to obtain information on the incidence of all cancers in the family history. The information obtained may initiate genetic testing, leading to the identification of mutations that are related to cancer in the current or next generation. In addition, these mutations may offer alternative treatment options for patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24017724
003      
CZ-PrNML
005      
20241016081844.0
007      
ta
008      
241008e20240913ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euros.2024.08.011 $2 doi
035    __
$a (PubMed)39314911
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
245    10
$a Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes / $c K. Hemminki, LA. Kiemeney, AK. Morgans, A. Ranniko, R. Pichler, O. Hemminki, Z. Culig, P. Mulders, CH. Bangma
520    9_
$a UNLABELLED: Early recognition of hereditary urological cancers may influence diagnostic and therapeutic decision-making, and potentially alter the fate of patients and family members. Here, we introduce readers to the current knowledge on germline genetic testing and clinical practice in prostate, bladder, renal, and testicular carcinoma. Considering all urological cancer patients, routine inquiries about familial cancer history should become a standard practice in clinical settings. If suspicion arises, patients can opt for two avenues: referral to genetic counseling or undergoing genetic tests after consultation with the treating urologist. PATIENT SUMMARY: Tumors of the urogenital tract (prostate, kidney, bladder, and testes) can sometimes be related to genetic mutations that are present in all the cells of the body. Such mutations can be inherited and run in families. Therefore, it is relevant to obtain information on the incidence of all cancers in the family history. The information obtained may initiate genetic testing, leading to the identification of mutations that are related to cancer in the current or next generation. In addition, these mutations may offer alternative treatment options for patients.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kiemeney, Lambertus A $u Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands
700    1_
$a Morgans, Alicia K $u Survivorship Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
700    1_
$a Ranniko, Antti $u Research Program in Systems Oncology and ICAN-Digital Precision Cancer Medicine Flagship, Department of Urology, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Pichler, Renate $u Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Hemminki, Otto $u Research Program in Systems Oncology and ICAN-Digital Precision Cancer Medicine Flagship, Department of Urology, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Culig, Zoran $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Mulders, Peter $u Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands
700    1_
$a Bangma, Chris H $u Department of Urology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The Netherlands
773    0_
$w MED00207999 $t European urology open science $x 2666-1683 $g Roč. 69 (20240913), s. 13-20
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39314911 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081839 $b ABA008
999    __
$a ok $b bmc $g 2196357 $s 1229675
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 69 $c - $d 13-20 $e 20240913 $i 2666-1683 $m European urology open science $n Eur Urol Open Sci $x MED00207999
LZP    __
$a Pubmed-20241008

Find record

Citation metrics

Archiving options